Soluble Therapeutics Acquired by CytoBioscience more

Young Living Essential Oils Partners with TFS Sandalwood Farms more

Beaufort Memorial Using Xenex Germ-Zapping Robot to Destroy Pathogens That Can Cause Hospital-Acquired Infections more

DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology more

Cartersville Medical Center Unveils Xenex Germ-Zapping Robot more

DNAtrix enters into license agreement with University of Florida to develop new oncolytic virus platform more

DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform more

Supportive Data for the Use of Santalis Pharmaceuticals’ East Indian Sandalwood Oil (EISO) for the Treatment of Psoriasis is Presented at International Conference more

Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD) more

DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA more

Robotics: Germ-Zappers Are Saving Lives

A hospital is no place to be… especially if you’re sick.

According to the World Health Organization (WHO), health care-associated infections (HAI) — infections acquired in healthcare settings that can lead to sepsis and/or death — “are the most frequent adverse event in health care delivery worldwide.”

Seven out of every 100 patients hospitalized in developed countries and 10 out of 100 hospitalized in developing countries will be diagnosed with at least one HAI.

That’s hundreds of millions of people getting sick — or even dying — because they sought medical treatment. And it costs healthcare providers a lot of money.

Remember “superbugs” — bacteria resistant to antibiotics? One in four HAI is caused by antibiotic-resistant bacteria.

That’s the next front in the war on HAI, according to a recent report from the Centers for Disease Control and Prevention (CDC).

The good news is there’s one robot capable of fighting the HAI war and the increasingly critical antimicrobial resistance battle.

Meet the world’s only full-spectrum ultraviolet germ-zapping robot — the creation of Xenex Disinfection Services.

Indeed, it does look just like something out of the Star Wars franchise.

The Xenex robot is now used in more than 300 hospitals in the United States, deployed to clean up isolation rooms, operating rooms, general patient care rooms, contact precaution areas, emergency departments, bathrooms, and even public spaces.

On March 9, 2016, Xenex introduced the LightStrike, a new product that kills six antibiotic-resistant bacteria identified by the CDC as “urgent or serious threats to health.”

These include carbapenem-resistant Enterobacteriaceae (CRE); methicillin-resistant Staphylococcus aureus (MRSA); ESBL-producing Enterobacteriaceae (extended-spectrum β-lactamases); vancomycin-resistant Enterococcus (VRE); multidrug-resistant Pseudomonas aeruginosa; and multidrug-resistant Acinetobacter.

Xenex was founded by epidemiologists Dr. Julie Stachowiak and Dr. Mark Stibich in 2008.
Venture capitalist Morris Miller provided initial funding for the business, which reincorporated as Xenex Healthcare Services and relocated from Houston to Austin, Texas, in 2009.
The first version of its Pulsed Xenon Full Spectrum UV System hit the market in 2010.

A 2011 study led by Stachowiak and Stibich and published by the journal Infection Control & Hospital Epidemiology found “a statistically significant reduction in microbial load and eliminated VRE [vancomycin-resistant Enterococci] on sampled surfaces” treated with the Xenex system.

According to the study, Xenex’s system was “20 times more effective at killing dangerous pathogens than traditional housekeeping methods.”

Xenex sold its first robot shortly thereafter, in 2012.

A second peer-reviewed study, published by the Journal of Infection Prevention in 2013, found that Cone Health, a not-for-profit network of healthcare system based in Greensboro, North Carolina, saw a 56% reduction in its rate of hospital-acquired MRSA (methicillin-resistant
Staphylococcus aureus) infections after it introduced Xenex robots as part of a larger effort to combat HAI.

Subsequent peer-reviewed studies have shown a 56% reduction in hospital-acquired C. diff (Clostridium difficile) and a 70% decrease in ICU C. diff infections, due in part to use of a Xenex robot.

Xenex has raised approximately $40 million in funding across three rounds subsequent to Miller’s initial investment.

A $25 million round announced in January 2015 included significant interest from overseas investors, a strong sign that Xenex will be able to find markets for its products in Europe and Asia.

As New Scientist reported last week, “The first-ever study of hospital-acquired infections in European hospitals has found that the combined health impact of these infections is twice that of the combined burden of 32 infections caught outside hospitals, including flu, HIV and tuberculosis.”

A fresh round of $3 million in September from Tectonic Ventures should allow the company to expand its sales efforts and to fund new product development, as it continues to penetrate a market defined by the more than 750 hospitals fined for HAI last year.

CDC statistics show that HAI kill about 200 people a day in the United States alone.

Well, Xenex’s good robots are about to make hospitals great — well, safe, at least — again.

Source: http://www.wallstreetdaily.com/2016/ back

DHR first in RGV with xenon UV disinfection systems more

neoSurgical® Announces CE Mark Approval of the neoClose® Laparoscopic Port Closure Device more

Germ-zapping robot named 'Gronk' helped kill MRSA at Mass. high school more

Doctors Hospital at Renaissance is First in Rio Grande Valley to Deploy Xenex Germ-Zapping Robots more

Bio2 Medical's Angel Catheter successfully placed in first two patients more

Cardiovate Develops First Bioabsorbable Vascular Graft more

Funding San Antonio’s Biotech Ecosystem more

A biotech groups to share in major military contract to manufacture stem cells more

Robot disinfecting rooms at Life Line Hospital in Wintersville more

Life Line Hospital is the First Long Term Acute Care Hospital in Ohio to Enhance Patient Safety by Deploying a Xenex Germ-Zapping Robot more

Robots show Marin, Sonoma hospitals the light on disinfection more

Santalis Pharmaceuticals Announces Issuance of Patent for the Use of Sandalwood Oil to Treat Cancers more

Santalis Pharmaceuticals Initiates a Phase 2 Study of Mild, Moderate and Severe Atopic Dermatitis - Enrolls First Patient Into Its Australian Clinical Trial Site more

With Scaffold for Regenerating Arteries, Cardiovate Raises $350,000 more

Bluegrass Vascular Secures CE Mark Approval and Announces Successful Commercial Use of The Surfacer® Inside-Out® Access Catheter System more

Bio2 Medical® Closes on $3 Million of Venture Debt Financing more

Tropical Forestry Services prepares for first Indian sandalwood shipment to China more

Bio2 Medical® Announces 510(k) Clearance from the FDA for the Angel® Catheter, the First Ever Prophylactic Use Indication for a Medical Device for Pulmonary Embolism more

International perfumery competition winner tours Indian sandalwood plantations in the Kimberley more

SA biotech firm drawing global interest year after moving from Germany more

TFS Corporation makes bond offer more

New robot system at USC Verdugo Hills Hospital uses UV light to disinfect hospital rooms more

DNAtrix wins $2 million FDA grant for cancer immunotherapy more

DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401 more

TFS Corporation - July 2016 Update more

StemBioSys reaches European distribution agreement for its products more

BRIEF-Diamyd Medical: Cellaviva appointed European distributor for StemBioSys more

DNAtrix Receives European Medicines Agency PRIME Designation more

DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone's MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma more

Australia forestry company TFS Corp gets two ratings upgrades more

Tour of Texas: Valence, Stellarray, Flux Farms, A&M, StemBioSys more

StemBioSys reaches distribution agreement for its products in South Korea more

Camden Clark Medical Center Introduces Newest Xenex Germ-Zapping Robot more

MPR Client Innovative Trauma Care Wins Gold at 2016 Medical Design Excellence Awards more

Santalis Pharmaceuticals Announces Positive Results From a Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation for the Treatment of Mild-to-Moderate Plaque Psoriasis more

Texas among top states in foreign investments more

How Your Family Drives Business Decisions more

StemBioSys enters distribution agreement for its products in Japan more

San Antonio biotech firm takes big step toward global expansion more

Vidant Edgecombe Hospital adds Xenex Germ-Zapping Robot to reduce HAIs more

This hospital spent $300,000 on giant, superbug-killing robots more

Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) to Treat Mild to Moderate Plaque Psoriasis more

SA biotech company backing fed stem cell bill to cut red tape from regulatory pathway more

Bexar County added 4,350 jobs last year, study says more

Springfield Clinic unveils Xenex Germ-Zapping Robot for infection control more

San Antonio venture capital funding fell last year more

neoSurgical Limited Expands Indications For neoClose Device more

Bio2 Medical Closes Series D Preferred Stock more

TFS undertakes $60 million placement more

Bluegrass Vascular Technologies’ catheter system used on first patient more

Cytocentrics refunds $100,000 in economic development funds to city more

Bluegrass Vascular Technologies Announces First Clinical Use of the Surfacer® Inside-Out® Access Catheter System in Europe. more

Long-term acute care facility in California implements Xenex germ-zapping robot more

Robotic housekeeper disinfects the rooms at Modesto hospital more

Aerin Medical raises $16.7M, adds new board members more

Brokers Sniff Sweet Potential In TFS Corp more

East Indian sandalwood oil (EISO) is the key ingredient in these grooming products for dogs more

Santalis Pharmaceuticals Completes the Spin-Off of Roxy’s Remedies Inc. more

TFS Corporation - January 2016 Update more

DNAtrix's Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation more

Strategic partnering deal with Cytocentrics more

Cytocentrics CEO: San Antonio to get big boost from new deal more

GhostBuster the Lab Mix Reviews Roxy’s Remedies Pure Relief Spray Gel more

Avera McKennan Addresses Patient Safety with Germ-Zapping Robots more

Santalis Pharmaceuticals Announces Positive Results from a Study of Pediatric Patients with Eczema more

Santalis announces positive results for pediatric atopic dermatitis treatment more

Here’s why the TFS Corporation Limited share price soared 28% today more

Cytocentrics gaining traction in San Antonio more

The Drugstore Acne Fighters Dermatologists Swear By more

neoSurgical® Begins Postmarket Surveillance Study more

Santalis Announces First Subject Enrolled in Phase 2 Trial more

BiO2 Medical Reports Positive Advancement of the Series D Round of Funding more

Germany’s Axiogenesis to collaborate with new San Antonio biotech company more